5. Repros Reproach
What more can we say Dumbest fans? Res ipsa loquitur . And if that wasn't enough, TheStreet's Adam Feuerstein reported that at another point during the conference call, Podolski disclosed that a nurse at one of the Androxal clinical trial sites fabricated baseline sperm counts for patients. When Repros discovered the data fraud, the company changed the fishy numbers and everything turned out fine. A second phase III study of Androxal is under way with enrollment expect to wrap in May. Podolski insisted the data announced Thursday should convince investors that the second study will also be positive. Repros bulls are probably looking forward to the next report and not just for its racy content. Shares of the stock spiked nearly 80% on Podolski's pronouncements despite the trial's inconsistencies and the missing Androxal data. Then again, fundamentals aren't really a factor when it comes to Repros stock. Nearly half the company's shares have been sold short, opening up the possibility for the bulls to once again squeeze the bears where it hurts. And that can't be good for their sperm counts either.